# Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

> PubMed lists PMID 42133304 in JAMA as Journal Article, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42133304-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-15
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42133304-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42133304-teriparatide-v1.json
- Content SHA-256: `1a4c655533d20a5eccbd8113b15d4f97435630664c6d88ea48331ac62e4afebe`

## Claims and source pins

### Headline

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

### Summary

PubMed lists PMID 42133304 in JAMA as Journal Article, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

### Paragraph 1

PubMed lists PMID 42133304 in JAMA as Journal Article, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

## Sources

<a id="source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3"></a>
- **Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. · retained source version 1:2026-07-15:current:b413e30416a35b6b7cbd6cd1f0e8f020dd1cb507da91e5910b8c165b3df61cc9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42133304/) (`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42133304-teriparatide-v1.json SHA-256: 1a4c655533d20a5eccbd8113b15d4f97435630664c6d88ea48331ac62e4afebe.